FMR LLC Reports New 6.1% Passive Stake in Avalo Therapeutics (AVTX)

On June 5, 2026, FMR LLC filed a Schedule 13G/A with the SEC, reporting a significant new ownership stake in Avalo Therapeutics, Inc. (AVTX). As of the event date on May 29, 2026, FMR LLC and associated reporting person Abigail P. Johnson beneficially own 3,188,401 shares of common stock, representing a 6.1% ownership interest in the company. This filing marks an increase from a previously reported 0.0% position, indicating a substantial acquisition of shares. FMR LLC holds sole dispositive power over the entire 3,188,401 shares and sole voting power over the same amount. The securities were acquired in the ordinary course of business and are not held for the purpose of changing or influencing control of the issuer. Avalo Therapeutics is a clinical-stage biotechnology company headquartered in Wayne, Pennsylvania. The filing was submitted as Amendment No. 2, updating the firm's previous regulatory disclosures regarding its holdings in the issuer.